Neomycin Sulfate Injection

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including beta-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6) produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.

Streptavidin sulfate. Its chemical name is: O-2-amino-2,3,4,5-tetrateoxy-5-(methylamino)-2-D-erythro-hexopyranosyl-(14)-O-[3-deoxy-4-C-methyl-3-(methylamino)-b-L-arabinopyranosyl-(16)-2-deoxy-D-streptamine sulfate.

Colorless or almost colorless clear liquid.

This product is mainly used for respiratory tract, urinary tract, abdominal cavity and trauma infections caused by Gram-negative bacteria such as Escherichia coli, Klebsiella, Proteus, Enterobacter, Serratia, Pseudomonas aeruginosa, etc. It can also be used for sepsis.

Intramuscular injection or intravenous drip after dilution. Intramuscular injection for adults: 60-80 mg at a time, up to 120 mg if necessary, 2-3 times a day; intravenous drip: 60 mg at a time (2 vials at a time), add to 100 ml of sodium chloride injection and drip at a constant speed, and the drip should be completed within 1 hour. Children should be given 3-4 mg/kg of body weight in 2-3 doses.

1Common symptoms include hearing loss, tinnitus or fullness in the ears (ototoxicity), hematuria, significantly reduced frequency of urination or decreased urine volume, loss of appetite, extreme thirst (nephrotoxicity), unsteady gait, dizziness (ototoxicity, vestibular effects), nausea or vomiting (ototoxicity, vestibular effects, nephrotoxicity). 2Rare symptoms include vision loss (optic neuritis), dyspnea, drowsiness, extreme weakness (neuromuscular blockade), allergic reactions such as rashes, changes in blood counts, changes in liver function, digestive tract reactions, pain at the injection site, nodules, phlebitis, etc. 3Rarely, anaphylactic shock.

1. Patients who are allergic to this product or other aminoglycosides and bacitracin, or who have family members who have developed deafness or other hearing loss due to the use of streptomycin are contraindicated. 2. Patients with renal failure are contraindicated.

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4 This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5 This product should not be used in combination with other nephrotoxic or ototoxic drugs, or applied sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6 This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7 This product can often achieve synergistic effects when used in combination with beta-lactams (cephalosporins or penicillins). 8 This product mixed with beta-lactams (cephalosporins or penicillins) can lead to mutual inactivation, and must be dripped in separate bottles when used in combination.

Keep tightly closed in a cool, dark place.

1 ml: 30 mg (30,000 units)

Jiangxi Pharmaceutical Co., Ltd.

• Founded in:

  1996-06-10

• Address:

  No. 758, Huiren West Avenue, Xiaolan Industrial Park, Nanchang County, Nanchang City, Jiangxi Province

• Tax NO.:

  913600001582615429

• Registered Funds:

  295.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view